1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Montelukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human colon cancer
(
- Contribution to journal › Article
- 2013
-
Mark
CysLT1R Antagonists Inhibit Tumor Growth in a Xenograft Model of Colon Cancer.
(
- Contribution to journal › Article